0.4659USD+4.93%Mkt Cap: 22.55M USDP/E: —Last update: 2026-05-26
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap22.55M USD
Enterprise Value-17.10M USD
Revenue (TTM)—
Gross Profit-41.73M USD
Net Income (TTM)-60.82M USD
Revenue/Share—
Last Price0.4659 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees39
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.43
PEG—
EV/EBITDA0.32
EV/Revenue—
P/S—
P/B1.68
EPS (TTM)-1.21
EPS (Forward)-0.99
52W Range
0.40403% of range2.380
52W High2.380 USD
52W Low0.4040 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-245.20%
ROA-87.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.29M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-16.38%
Net Debt-37.63M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity1.52
Current Ratio1.26
Quick Ratio1.21
Book Value/Sh0.2510 USD
Cash/Share0.9560 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.48.60M
Float41.23M
Insiders5.61%
Institutions35.00%
Short Interest
Short Ratio2.1d
Short % Float1.81%
Short % Out.1.50%
Shares Short726.86K
Short (prev mo.)1.38M
Technical
SMA 500.7786 (-40.2%)
SMA 2001.019 (-54.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)516.07K
Avg Vol (10d)896.03K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—